Featuring the SCIEX Triple Quad™ 7500 LC-MS/MS System – QTRAP ® Ready, powered by SCIEX OS Software
Lei Xiong1 , Ian Moore2
1SCIEX, USA, 2SCIEX, Canada
Cyclic peptides have been identified as important therapeutic modalities, this is related to their stability in blood and potential for oral dosing. LC-MS method development to quantify trace level cyclic peptides in biological matrices has remained challenging. The high baseline interference in matrices requires the method to be highly selective to obtain desired S/N. They are often resistant to CID fragmentation, due to their knotted tertiary structure and/or nonmobile proton.
Natriuretic peptide (NP) family is a group of genetically distinct cyclic peptides with similar structure, containing an amino acid ring formed by a disulfide bond between two cysteine residues (Figure 1). They have emerged as important candidates for development of diagnostic tools and therapeutic agents in cardiovascular diseases.1 In this project, two peptides in the NP family, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are selected as the model analyte to evaluate the quantification capability of SCIEX Triple Quad™ 7500 LC-MS/MS System. The OptiFlow® Pro Ion Source together with D Jet™ Ion Guide offers significantly improved sensitivity for cyclic peptide quantification, through improved desolvation and focusing to improve MRM performance. Both ANP and BNP are solidly quantified at 0.05 ng/mL in rat plasma, multiple times lower than the previously published LLOQ.2 Outstanding reproducibility, precision, accuracy, and linearity are also achieved, proving the workflow robustness in parallel with the superior sensitivity.